Abstract
EPO for stroke therapy - Is there a future for further clinical development?
Highlights
Editorial The recently published double-blind, placebo-controlled, randomized phase II/III German Multicenter EPO Stroke Trial was conducted to evaluate the efficacy and safety of Erythropoietin (EPO) in stroke patients [1]
In this Editorial we discuss potential reasons for the negative results of the German Multicenter EPO Stroke Trial, which contrasted the findings of a clinical pilot trial and several preclinical studies that showed beneficial effects of EPO [2,3]
An underpowering caused by the study design of the German Multicenter EPO Stroke Trial
Summary
Editorial The recently published double-blind, placebo-controlled, randomized phase II/III German Multicenter EPO Stroke Trial was conducted to evaluate the efficacy and safety of Erythropoietin (EPO) in stroke patients [1]. In this Editorial we discuss potential reasons for the negative results of the German Multicenter EPO Stroke Trial, which contrasted the findings of a clinical pilot trial and several preclinical studies that showed beneficial effects of EPO [2,3]. 2. An underpowering caused by the study design of the German Multicenter EPO Stroke Trial. Germany Full list of author information is available at the end of the article ized to EPO treatment or placebo the efficacy was lower compared to studies in which randomization was not reported [7].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call